Tuvutromstat
Small molecule
Also known as IDE397
Evidence outlook · results not reported
NCT05975073 · MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors
The lead study uses a design that frequently fails to replicate under controlled conditions, and its results have not been reported. This tier describes the design, not an outcome.
NCT05975073: The study is a nonrandomized, open-label, single-arm dose-exploration and dose-expansion trial without a placebo or active comparator. Its Part 2 primary outcome is objective tumor response by RECIST 1.1, but no results are posted, so whether the primary endpoint was met cannot be determined.
Also in development:Bladder Cancer · Phase 1
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05975073 NCT05975073 · MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors The study is a nonrandomized, open-label, single-arm dose-exploration and dose-expansion trial without a placebo or active comparator. Its Part 2 primary outcome is objective tumor response by RECIST 1.1, but no results are posted, so whether the primary endpoint was met cannot be determined. Registry: NCT05975073 | 1/2 | Part 1: Number of Participants Experiencing Dose Limiting Toxicities (DLTs) (Day 1 up to Day 21); Part 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) (Day 1 up to approximately 2.5 years); Part 1: Number of Participants Experiencing Serious Adverse Events (SAEs) (Day 1 up to approximately 2.5 years); Part 2: Objective Response (OR) per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Day 1 up to approximately 2.5 years) 2026-02-25 | Results not posted; external-source review pending | Weak signal | link ↗ |
View 1 more trial
NCT04794699 NCT04794699 · Solid Tumor Registry: NCT04794699 | 1 | Dose-limiting Toxicities (DLTs) of IDE397 (21 days following the first dose of IDE397); Dose-limiting Toxicities (DLTs) of IDE397 in combination with sacituzumab govitecan (21 - 28 days following the first dose of IDE397); Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of IDE397 (Approximately 2 years); Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of IDE397 in combination with sacituzumab govitecan (Approximately 2 years); To evaluate preliminary anti-tumor activity of IDE397 as monotherapy and in combination with sacituzumab govitecan-hziy in expansion arms (Approximately 2 years) 2027-01-07 | In progress: results expected 7 Jan 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Bladder Cancer: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tuvutromstat: this drug | Phase 1 | Small molecule | MAT2A | not yet graded | No reviewed efficacy summary in this indication | |
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Enfortumab Vedotin | Approved | Antibody–drug conjugate | Nectin-4 | Partial signal | NCT03474107: Overall Survival (OS) (From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)): Enfortumab Vedotin 1.25 mg/kg 12.88 months (95% CI 10.58 to 15.21) | Chemotherapy 8.97 months (95% CI 8.05 to 10.74) NCT03219333: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) (Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)): Enfortumab Vedotin - Cohort 1 44 Percentage of Participants (95% CI 35.1 to 53.2) | Enfortumab Vedotin - Cohort 2 51.7 Percentage of Participants (95% CI 40.8 to 62.4) | |
| Nogapendekin Alfa Inbakicept (Anktiva) | Approved | Protein / enzyme therapeutic | IL-15 superagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Cetrelimab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Tremelimumab | Phase 3 | Monoclonal antibody | CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Visugromab | Phase 2 | Monoclonal antibody | GDF-15 | Weak signal | NCT06059547: Two primary endpoints, no significance test reported (exploratory). Pathologic complete response: 33.3% nivolumab + visugromab (n=15 evaluable) vs 7.1% nivolumab + placebo (n=14 evaluable). Objective response by RECIST 1.1: 60.0% vs 14.3%. Major pathologic response (secondary): 66.7% vs 21.4%. | |
| MK-3120 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-2005 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Avipendekin Pegol | —(overall) | Cytokine | IL-15 receptor | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Tuvutromstat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.